NxStage Medical, Inc. (NASDAQ:NXTM) Announces Quarterly Earnings Results
NxStage Medical, Inc. (NASDAQ:NXTM) announced its quarterly earnings data on Monday. The medical device company reported ($0.03) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.03), MarketWatch Earnings reports. NxStage Medical had a negative return on equity of 2.31% and a negative net margin of 1.25%. The firm had revenue of $92.20 million for the quarter, compared to analysts’ expectations of $96.47 million. During the same quarter in the prior year, the firm posted ($0.03) earnings per share. NxStage Medical’s revenue for the quarter was up .0% compared to the same quarter last year.
NxStage Medical (NASDAQ:NXTM) opened at 23.14 on Monday. The company’s market capitalization is $1.52 billion. The stock’s 50 day moving average price is $24.08 and its 200 day moving average price is $25.81. NxStage Medical has a 12-month low of $20.45 and a 12-month high of $30.80.
In other NxStage Medical news, President Joseph E. Turk, Jr. sold 7,000 shares of NxStage Medical stock in a transaction on Thursday, August 3rd. The shares were sold at an average price of $22.98, for a total transaction of $160,860.00. Following the completion of the sale, the president now owns 82,903 shares of the company’s stock, valued at approximately $1,905,110.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Joseph E. Turk, Jr. sold 1,000 shares of NxStage Medical stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $25.19, for a total transaction of $25,190.00. Following the sale, the president now directly owns 75,903 shares of the company’s stock, valued at approximately $1,911,996.57. The disclosure for this sale can be found here. In the last three months, insiders sold 29,150 shares of company stock valued at $669,351. 4.70% of the stock is currently owned by company insiders.
Several analysts have issued reports on NXTM shares. Craig Hallum started coverage on NxStage Medical in a research note on Tuesday, June 27th. They set a “buy” rating and a $32.00 price objective on the stock. Canaccord Genuity restated a “buy” rating and set a $32.00 price objective on shares of NxStage Medical in a research note on Monday, May 8th. Jefferies Group LLC cut their price objective on NxStage Medical from $38.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, May 10th. BidaskClub upgraded NxStage Medical from a “hold” rating to a “buy” rating in a research note on Friday, June 30th. Finally, Northland Securities cut NxStage Medical from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $30.50.
TRADEMARK VIOLATION WARNING: This piece was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/07/nxstage-medical-inc-nasdaqnxtm-announces-quarterly-earnings-results.html.
NxStage Medical Company Profile
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.